Results 31 to 40 of about 362,523 (334)

Deep segmentation networks predict survival of non-small cell lung cancer [PDF]

, 2019
Non-small-cell lung cancer (NSCLC) represents approximately 80-85% of lung cancer diagnoses and is the leading cause of cancer-related death worldwide. Recent studies indicate that image-based radiomics features from positron emission tomography-computed
Allen, Bryan, Baek, Stephen, Baek, Stephen, Buatti, John, Cabel, Katherine, Diehn, Maximilian, Gannon, Maggie, He, Yusen, Kim, Yusung, Loo, Billy, Plichta, Kristin, Seyedin, Steven, Smith, Brian, Sun, Zhiyu, Tong, Ling, Wu, Jia, Wu, Xiaodong   +16 more
core   +2 more sources

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis

Open Medicine, 2023
The efficacy of immune checkpoint inhibitors (ICIs) on KRAS-mutant advanced non-small cell lung cancer (NSCLC) remains controversial. This retrospective study compared the effects of ICIs treatment and chemotherapy on the prognosis of patients with KRAS ...
Gu Xiaodong, Si Jinfei, Guan Yelan, Xu Yibing, Shao Lan, Zhang Yiping, Xu Chunwei, Pan Weiwei, Lu Yuanzhi, Song Zhengbo, Wang Wenxian   +10 more
doaj   +1 more source

Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. [PDF]

, 2013
BackgroundPreclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models.MethodsWe conducted a ...
Bastida, Christel, Falchook, Gerald S, Fu, Siqing, Hong, David S, Jiang, Yunfang, Kurzrock, Razelle, Morgan-Linnell, Sonia K, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph   +11 more
core   +2 more sources

Precision Surgery in NSCLC

Cancers, 2023
Non-small cell lung cancer (NSCLC) is still one of the leading causes of death worldwide. This is mostly because the majority of lung cancers are discovered in advanced stages. In the era of conventional chemotherapy, the prognosis of advanced NSCLC was grim. Important results have been reported in thoracic oncology since the discovery of new molecular
Cannone, Giorgio, Comacchio, Giovanni Maria, Pasello, Giulia, Faccioli, Eleonora, Schiavon, Marco, Dell'Amore, Andrea, Mammana, Marco, Rea, Federico   +7 more
openaire   +3 more sources

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. [PDF]

, 2018
BACKGROUND:We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between liquid biopsy ...
Mambetsariev, Isa, Salgia, Ravi, Vora, Lalit, Yu, Kim Wai   +3 more
core   +1 more source

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Медицинский совет, 2019
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily.
K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba   +7 more
doaj   +1 more source

lncRNA SLC9A3-AS1 Promotes Oncogenesis of NSCLC via Sponging microRNA-760 and May Serve as a Prognosis Predictor of NSCLC Patients

Cancer Management and Research, 2022
Xiuming Huang,* Mingfang Huang,* Minbiao Chen, Xianshan Chen Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xianshan ...
Huang X, Huang M, Chen M, Chen X
doaj  

Simulating non-small cell lung cancer with a multiscale agent-based model [PDF]

, 2007
Background The epidermal growth factor receptor (EGFR) is frequently overexpressed in many cancers, including non-small cell lung cancer (NSCLC). In silcio modeling is considered to be an increasingly promising tool to add useful insights into the ...
Deisboeck, Thomas S., Sagotsky, Jonathan, Wang, Zhihui, Zhang, Le   +3 more
core   +5 more sources

Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation

Cancer Management and Research, 2021
Tianxiang Zhang,1 Wei Li,2 Meng Gu,1 Ziyu Wang,1 Shijie Zhou,2 Xuefeng Hao,1 Weiying Li,1 Shaofa Xu1 1Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research ...
Zhang T, Li W, Gu M, Wang Z, Zhou S, Hao X, Li W, Xu S   +7 more
doaj  

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer

Cancer Biology & Medicine, 2022
Objective: The novel compound GCJ-490A has been discovered as a pan-histone deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3, and HDAC6.
Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, Yi Chen   +7 more
doaj   +1 more source